samedan logo
 
 
 
spacer
home > ebr > spring 2002 > vaccination - who should we trust?
PUBLICATIONS
European Biopharmaceutical Review

Vaccination - Who Should We Trust?

Increasing numbers of concerned parents in the UK are rebelling against MMR as theonly 'safe' vaccination alternative for their children. According to the results of a recent Guardian/ICM opinion poll (1), some 75 per cent of parents interviewed would like the UK Government to provide free separate measles, mumps and rubella vaccinations for their children. The overall results of the poll suggest that all the recent efforts made by the Government have had little or no impact in reducing popular anxiety over this matter. Only 20 per cent of those included in the survey said they would "trust a lot" the advice given by politicians and their officials, with a worrying 30 per cent disregarding it altogether. So is this a new crisis of trust in the governing bodies or are we facing the same problems over and over again? With the number of measles cases rising not only in the UK but in other European countries such as Germany - in some incidents to the point of epidemic clusters - we should all be reminded of the potential horrors of the infections being prevented by mass vaccination: a wider incidence of diseases striking the population, in some cases with potentially fatal results.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Dr Ian Gibson, Member of Parliament for Norwich North and Chair of the Commons Science and Technology Select Committee

Dr Ian Gibson was educated at Dumfries Academy and later attended Edinburgh University, where he was awarded a BSc and a PhD. He was a Royal Society Fellow at Edinburgh, and a Postdoctoral Fellow at Indiana University. Ian was also a visiting Professor at the University of Washington before joining the University of East Anglia (UEA) as a Lecturer in 1965. He was made a Senior Lecturer at UEA in 1970 and served as Dean of the School of Biological Sciences from 1991 to 1997. At UEA Ian was the head of a research team investigating various forms of cancer. In 1997 he was elected as Member of Parliament for Norwich North, a seat he kept after the 2001 election. In Parliament Ian specialised in science issues, particularly those relating to cancer research, founding the All Party Group on Cancer. During the last Parliament he was a member of the Commons Science and Technology select Committee, which he currently chairs, and was elected Chair of the Parliamentary Office of Science and Technology and the Parliamentary and Scientific Committee, a position he still holds.

spacer
Dr Ian Gibson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Pharmapack Moves to May 2021

Paris, 30 July 2020: Pharmapack Europe (#pharmapackeu), organised by Informa Markets, moves to May 2021 (19-20) to provide attendees, exhibitors and the pharma packaging community the best season and format. The decision follows a careful review with key stakeholders, with the exhibition continuing at its usual location: Hall 7.2 at Paris Expo, Porte de Versailles.
More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody

RSSL

Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement